Structure-Based Drug Discovery with Deep Learning.

Area of Science:

• Computational chemistry
• Drug discovery
• Chemical biology

Background:

• Deep learning (AI) shows significant promise in drug discovery, aiding tasks like protein structure prediction and molecular bioactivity assessment.
• Current deep learning applications in drug discovery predominantly utilize ligand-based methods.
• Structure-based drug discovery, however, offers potential for addressing complex challenges like affinity prediction and mechanism elucidation for novel targets.

Purpose of the Study:

• To review prominent algorithmic concepts in structure-based deep learning for drug discovery.
• To highlight the potential of AI-guided structure-based approaches in reviving drug discovery paradigms.
• To forecast future opportunities, applications, and challenges in this field.

Main Methods:

• Summarizing key deep learning methodologies applied to structure-based drug discovery.
• Analyzing the impact of advances in deep learning algorithms and protein structure prediction accuracy.
• Reviewing existing literature on AI-driven structure-based drug design.

Main Results:

• Deep learning, particularly when combined with accurate protein structure predictions, is enabling a resurgence in structure-based drug discovery.
• Structure-based AI approaches can tackle previously intractable problems in drug discovery, including affinity prediction and kinetic property rationalization.
• The integration of AI facilitates the design of novel molecules and the understanding of binding mechanisms.

Conclusions:

• AI-driven, structure-based drug discovery represents a significant advancement with the potential to overcome current limitations.
• Further development in deep learning methodologies and data availability will accelerate the application of these techniques.
• The field is poised for growth, offering new avenues for identifying and developing therapeutics for challenging targets.